Frank Cackowski

Assistant Professor

Karmanos Cancer Institute
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (14)

Health disparities present a barrier to successful oncology treatment. The potential for precision oncology to reduce health disparities has not previously been analyzed. We performed a retrospective analysis of 12,627 patients from six major cancer centers whose tumors underwent molecular testing at Caris Life Sciences between 2010 and 2020. Kaplan–Meier and Cox regression were used to describe and analyze overall survival. The molecular and demographic features of the cohort were analyzed by χ 2 and ANOVA tests. Black patients composed 25% of the cohort and White patients 63%. Among this molecularly-tested cohort, there were minimal outcome differences based on race, geographic location, or poverty level. When analyzing the interaction of age, race, and sex, racial-based disparities were noted primarily for young non-White women in the study cohort but were more pronounced for men and women of all ages in the broader patient population within the Surveillance, Epidemiology, and End Results database. Mutations in five genes— APC , EGFR , STK11 , TP53 , and KRAS —were found to affect overall survival among our cohort, and their prevalence varied by race in specific tumor types. Real-world outcomes data in mutation-defined cohorts also provided additional context to previously reported therapeutic response trends. Our study shows that patients who undergo molecular testing display reduced racial health disparities compared with the general population, whereas persistent racial disparities are influenced by age and sex. Genomic-driven racial disparities should be examined at a tumor lineage-specific level. Increased access to molecular testing for all eligible patients may play a role in improving health equity. Significance: This study is the largest of its kind to analyze health disparities and genomic features among a diverse multiinstitutional cohort of patients who underwent molecular testing. Continuing to increase awareness of and access to molecular testing approaches may help to reduce cancer health disparities and improve outcomes for all patients.

Year:

2025

IFN-β induction after TLR1/2 stimulation associates with PBMC ELISpot responses to Fluzone, PHA, and CEFT (cytomegalovirus, EBV, Fluzone, and Tetanus peptide pool). A, ELISpot SFU after each indicated stimulant ( n = 77 CEFT, n = 79 Fluzone, n = 82 for others). B, Cell type–specific PBMC densities as a percentage of live single cells (bottom) separated by median IFN-β response after TLR1/2 stimulation ( n = 106, PRIME study). A and B, P values are from unpaired t test; mean + SEM is shown. C, Correlation (Spearman r ) of each indicated PBMC (ELISpot), serum (ELISA), or sip-T product metric (CD54 upreg and TNC) output with fold mock IFN-β values after TLR1/2 stimulation; (*) indicates FDR adjusted Q

Year:

2024

Mounting evidence links systemic innate immunity with cancer immune surveillance. In advanced metastatic castration-resistant prostate cancer (mCRPC), Black patients have been found to have increased inflammatory markers and longer survival after sipuleucel-T (sip-T) therapy, an FDA-approved, autologous cell therapy. We hypothesized these differences may be explained by previously reported ancestral differences in pattern recognition receptor signaling, which broadly governs innate inflammation to control adaptive immune cell activation, chemotaxis, and functionality. We discovered that peripheral blood mononuclear cell IFN-β responses to Toll-like receptor 1/2 (TLR1/2), a sensor of bacterial and gut microbiome constituents, associated with significantly longer survival after sip-T therapy in two separate cohorts of men with mCRPC (discovery cohort: n = 106, HR = 0.12; P = 0.019; validation cohort: n = 28, HR P = 0.047). Higher IFN-β induction after TLR1/2 stimulation was associated with lower HRs than biomarkers of vaccine potency and other prognostic factors in mCRPC. TLR1/2-dependent cytokine induction was stronger in Black individuals (1.2-fold higher for IFN-β; P = 0.04) but was associated with survival independently of race or numbers of vaccine-induced tumor antigen–specific T cells. IFN-β responses to TLR1/2 signaling correlated with increased numbers of IFN-γ producing T cells after broad, tumor antigen–independent stimulation. Thus, peripheral innate immunity differs by race, may predict survival after sip-T, and associates with peripheral T-cell functionality in men with mCRPC. Significance: The identification of factors that determine successful cancer immunotherapy, particularly in refractory tumor types like mCRPC, is urgently needed: both to identify patients that may benefit from such therapies and to uncover routes to sensitize patients with cancer to immunotherapy. Our work links functional peripheral immune responses with race and survival after cellular immunotherapy in men with mCRPC.

Year:

2024

TLR1/2 responses associate with post–sip-T survival independent of race and TLR1/2 SNP status. A–C, Survival stratified by race in the merged PRIME and KCI cohorts ( A ), PRIME cohort alone ( B ), or KCI cohort alone ( C ). D and E, Survival of White ( D ) or Black ( E ) patients from the merged (PRIME and KCI) cohorts stratified by respective cohort median (PRIME or KCI) IFN-β induction after TLR1/2 stimulation. F and G, Survival of the PRIME cohort (TLR1 SNP genotyping was not performed in the KCI cohort) stratified by TLR1 602 I/I or I/S vs. TLR1 602 S/S for all races ( F ) or for White patients ( G ). H and I, Survival of patients with TLR1 602 I/I or I/S SNP ( H ) or TLR 602 S/S ( I ) stratified by median IFN-β induction after TLR1/2 stimulation. HRs and 95% CI are from the Mantel–Haenszel test; P values are from the Mantel–Cox log-rank test. See Supplementary Fig. S7 for extended data.

Year:

2024

Stronger IFN-β responses to TLR1/2 stimulation associates with longer survival after sip-T therapy. A, HRs ± 95% CIs from a Cox proportional hazards model comparing induction of each cytokine (fold mock control) after TLR1/2 stimulation with PAM 3 CSK 4 for PRIME cohort (left) or KCI cohort (right) vs. survival; *, P B, Survival of patients tested for TLR1/2 responsiveness stratified by median IFN-β induction for PRIME (left) and KCI (right) cohorts; P values are from Mantel–Cox test, HR and 95% CIs are from Mantel–Haenszel test. C, Mean z -scores normalized for each cytokine and treatment were computed for the combined cohort of patients (PRIME and KCI, n = 108), excluding patients that were censored prior to 1,000 days due to incomplete follow-up. Z -scores for patients surviving >1,000 days ( n = 47) are shown and reflect enrichment/depletion relative to the broader cohort; asterisk indicates FDR adjusted (within each stimulant group) t test Q D, Fold mock treated MFI values for IFN-β after treatment with TLR1/2 stimulation comparing patients surviving 1,000 days from PRIME (top) or KCI (bottom) subcohorts from C ; P values are from unpaired t test and mean + SEM is shown. E, Cox proportional hazards model derived HRs ±95% CI and P values for indicated prognostic features and IFN-β. PSA values were not available for two patients, which were excluded from these analyses ( n = 104). See Supplementary Figs. S2 and S3 for extended data. MFI, mean fluorescence intensity.

Year:

2024

Study design and in vitro responsiveness of PBMCs from patients with mCRPC to PRR agonist prior to sip-T treatment. A, Banked pretreatment PBMCs from the PRIME sip-T discovery cohort ( n = 106) or KCI validation cohort ( n = 28) were subjected to DNA isolation, flow cytometry, and/or testing in an in vitro stimulation assay. Two hundred thousand PBMCs per well were plated and treated with no stimulation (mock) or stimulation (stim) with TLR1/2 (PAM 3 CSK 4 ), TLR4 (LPS), MDA5 (Poly I:C-LyoVec), or T-cell [anti (α)-CD3/28 antibodies] after 24 hours of culture. B–D, Supernatant cytokine release was measured after in vitro stimulation. B, Principal component analyses colored by treatment using raw MFI values for each analyte, each data point represents a single patient. C, Box and whisker plots (Boxes: median ± 25%–75% quartiles, whiskers = range) of fold mock MFI values for each cytokine in the PRIME study ( n = 106), each data point represents a single patient. D, Heatmaps of log (fold mock control) values are shown for the PRIME and KCI (validation) cohorts; asterisks denote FDR adjusted Q t test vs. 0 (no induction). MFI, mean fluorescence intensity.

Year:

2024

Black race and TLR1-602I SNP associate with stronger responses to TLR1/2 stimulation. A, Supernatant cytokine release separated by Black ( n = 15) vs. White ( n = 91) for each stimulation normalized to fold mock treatment control in the PRIME study; (*) Mann–Whitney test P B, TLR1-602 genotypes for each patient with sufficient DNA ( n = 88 White; n = 15 Black) were tested by PCR-RFLP; percentages of I/I or I/S vs. S/S by race are shown. C, Mean fold mock control cytokine induction by genotype is shown for each stimulus; asterisks indicate significant FDR-corrected unpaired t tests Q D, Mean fold mock control TLR1/2 induced cytokine induction by genotype for White vs. Black (all I/I or I/S); FDR-adjusted unpaired t test Q E, Heatmaps depict −log ( P values) from comparisons in B (cytokine induction by race) or C (cytokine induction by TLR1 SNP status) for each cytokine and treatment. See Supplementary Fig. S6 for extended data.

Year:

2024

Many solid tumors including breast cancer can exhibit early dissemination and dormancy—in which cancer cells spread early in the disease process and survive long periods without detectable growth. These early disseminated tumor cells sometimes reactivate and lead to incurable metastatic disease years or even decades after curative-intent therapy for the primary tumor. We are just beginning to understand the role of the immune system in this process in part because of improvements in immunocompetent models as well as technological advances such as single-cell genomics and spatial transcriptomics. In this issue of Cancer Research, Bushnell and colleagues showed that NK cells are important in this context. The authors found that disseminated tumor cells and quiescent cells express higher levels of MHC 1 but are resistant to NK-cell–mediated immunity. The proposed mechanism involves the STING pathway and transcription factors Sox2 and Bach1. As other studies have highlighted the importance of T-cell immunity, this work reaffirms the importance and diversity of immune regulation of dormancy and suggests the need for future studies to flesh out mechanistic details and predict when each type of immunity is most important. See related article by Bushnell et al., p. 3337

Year:

2024

Analysis of treatment-associated outcomes and effect of mutation status among patients in Caris CODEai clinico-genomic database. A and B, Kaplan–Meier analysis comparing posttreatment OS between patients with STK11 -mutated (mut, blue lines) and STK11 -wild type (wt, red lines) NSCLC treated with ( A ) carboplatin (no pembrolizumab) and ( B ) pembrolizumab (no carboplatin). C and D, Kaplan–Meier analysis comparing ( C ) posttreatment OS and ( D ) TOT between patients treated with pemetrexed (blue lines) and osimertinib (red lines) for EGFR -mut NSCLC. E and F, Kaplan–Meier analysis comparing posttreatment OS between patients with EGFR -mut (blue lines) and EGFR -wt (red lines) NSCLC treated with ( E ) osimertinib or ( F ) pemetrexed. G and H, Kaplan–Meier analysis comparing ( G ) posttreatment OS and ( H ) TOT between patients treated with fluorouracil (blue lines) and capecitabine (red lines) for colorectal cancer.

Year:

2024

Genomic features and clinico-demographic associations of cohort. A, Total number of tumors positive for each mutated gene. B, Percentage of total tumors from each study site for the top 20 most commonly mutated genes. C, Prevalence of co-mutations among APC , EGFR , STK11 , TP53 , and KRAS . Red indicates strong co-mutation whereas blue indicates mutual exclusivity. D, Percentage of indicated tumor types with mutations in APC , EGFR , STK11 , TP53 , and KRAS . E, Age of patients among (−) and (+) gene mutation cohorts. The red line indicates the median age. F, Ratio of males to females in (−) and (+) gene mutation cohorts. G, Percentage of total (−) and (+) cohorts composed by indicated racial groups. *, P P P

Year:

2024

Year:

2024

Year:

2024

Year:

2021

Year:

2021

Collaborators (16)

Greg Dyson

Professor

Wayne State University

UNITED STATES
View details

Andrew Armstrong

Professor

Duke Cancer Institute

UNITED STATES
View details

George Sledge

-

UNITED STATES
View details

Samuel Kareff

University of Miami School of Medicine

UNITED STATES
View details

Hirva Mamdani

Karmanos Cancer Institute

UNITED STATES
View details

Michael Brown

Assistant Professor

Duke University

UNITED STATES
View details

Julie Boerner

Associate Professor

Wayne State University

UNITED STATES
View details

Mohammed Al Hallak

Assistant Professor

Wayne State University School of Medicine

UNITED STATES
View details

Wei Chen

Professor

Wayne State University

UNITED STATES
View details

Lawrence G. Lum

Professor of Medicine

University of Virginia

UNITED STATES
View details

Elisabeth I. Heath

Wayne State University School of Medicine

UNITED STATES
View details

Ira Winer

Professor

Wayne State University

UNITED STATES
View details

Hasan Korkaya

Associate Professor

Augusta University

UNITED STATES
View details

Archana Thakur

Associate Professor

University of Virginia

UNITED STATES
View details

Michael Gunn

Professor

Duke University

UNITED STATES
View details

Gilberto Lopes

Associate Professor

Sylvester Comprehensive Cancer Center

UNITED STATES
View details